Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor Ker-047 for Treatment of Iron Refractory Iron Deficiency Anemia

Vera Hoving, Albertine Donker, Enrikas Vainorius, Harveen Dhillon Natarajan, Jenn Lachey, Simon Cooper, Dorine W. Swinkels, Saskia Schols

Blood (2022) 140 (Supplement 1): 2475–2476.

https://doi.org/10.1182/blood-2022-163698

Published: 2022

Journal Articles

Iron homeostasis during anemia of inflammation: a prospective study of patients with tuberculosis

Colin I. Cercamondi, Nicole U. Stoffel, Diego Moretti, Thomas Zoller, Dorine W. Swinkels, Christophe Zeder, Francis Mhimibra, Jerry Hella, Lukas Fenner, Michael B. Zimmermann

Blood (2021) 138 (15): 1293–1303.

https://doi.org/10.1182/blood.2020010562

Published: 2021

Includes: Supplemental data

Journal Articles

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Blood (2018) 132 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2018-99-118070

Published: 2018

Journal Articles

Towards an External Quality Assessment for Next Generation Sequencing in the Diagnosis of Rare Inherited Anaemias

Blood (2018) 132 (Supplement 1): 4936.

https://doi.org/10.1182/blood-2018-99-111609

Published: 2018

Journal Articles

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

Marlijn Hoeks, MD, Saskia Langemeijer, MD PhD, Louise De Swart, MD, Tim Bagguley, Corine van Marrewijk, PhD, David Bowen, MD PhD, Jaroslav Cermak, Eva Hellstrom-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, Marian G.J. Van Kraaij, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic J Culligan, Marta Krejci, MD PhD, Jackie Droste, PhD, Alexandra Smith, PhD, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2016) 128 (22): 4327.

https://doi.org/10.1182/blood.V128.22.4327.4327

Published: 2016

Journal Articles

The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism

Nienke Schotten, Pieternel C. M. Pasker-de Jong, Diego Moretti, Michael B. Zimmermann, Anneke J. Geurts-Moespot, Dorine W. Swinkels, Marian G. J. van Kraaij

Blood (2016) 128 (17): 2185–2188.

https://doi.org/10.1182/blood-2016-04-709451

Published: 2016

Includes: Supplemental data

Journal Articles

Hepcidin in the diagnosis of iron disorders

Domenico Girelli, Elizabeta Nemeth, Dorine W. Swinkels

Blood (2016) 127 (23): 2809–2813.

https://doi.org/10.1182/blood-2015-12-639112

Published: 2016

Includes: Supplemental data

Journal Articles

Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9

Blood (2015) 126 (25): 2734–2738.

https://doi.org/10.1182/blood-2015-09-659854

Published: 2015

Includes: Supplemental data

Journal Articles

The Donation Interval of 56 Days Requires Extension to 180 Days for Whole Blood Donors to Recover from Disturbances in Iron Homeostasis

Nienke N.Schotten, MSc, Pieternel C Pasker-de Jong, PhD, Diego Moretti, PhD, Michael Bruce Zimmermann, MD, Marian G Kraaij, MD PhD, Dorine W. Swinkels, MD PhD

Blood (2015) 126 (23): 774.

https://doi.org/10.1182/blood.V126.23.774.774

Published: 2015

Journal Articles

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Louise De Swart, MD, Chloé Reiniers, Tim Bagguley, David Bowen, MD PhD, Jaroslav Cermak, MD PhD, Eva Hellström-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, MD PhD, Gerwin Huls, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic Culligan, Marta Krejci, Corine van Marrewijk, Jackie Droste, PhD, Alexandra Smith, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2015) 126 (23): 2865.

https://doi.org/10.1182/blood.V126.23.2865.2865

Published: 2015

Journal Articles

A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjects a

Ulrich Moebius, PhD, Werner Feuerer, MD, Edgar Fenzl, MD, Rachel van Swelm, PhD, Dorine W. Swinkels, MD PhD, Andreas Hohlbaum, PhD

Blood (2015) 126 (23): 536.

https://doi.org/10.1182/blood.V126.23.536.536

Published: 2015

Journal Articles

Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women

Diego Moretti, Jeroen S. Goede, Christophe Zeder, Markus Jiskra, Vaiya Chatzinakou, Harold Tjalsma, Alida Melse-Boonstra, Gary Brittenham, Dorine W. Swinkels, Michael B. Zimmermann

Blood (2015) 126 (17): 1981–1989.

https://doi.org/10.1182/blood-2015-05-642223

Published: 2015

Includes: Supplemental data

Journal Articles

International Comparison Study of Toxic Iron Assays in Patients with Iron Overload Disorders

Louise De Swart, MD, Jan C.M. Hendriks, Lisa Van der Vorm, Ioav Z. Cabantchik, PhD, Patricia J. Evans, PhD, Eldad A. Hod, MD, Gary M. Brittenham, MD, Yael Furman, Mirian C.H. Janssen, MD, Bart J Biemond, MD, Marius A. MacKenzie, MD PhD, Vera E.J.M. Mattijssen, MD, Raffaella Origa, MD, Renzo Galanello, MD, Robert C. Hider, Dorine W. Swinkels, MD PhD

Blood (2014) 124 (21): 4033.

https://doi.org/10.1182/blood.V124.21.4033.4033

Published: 2014

Journal Articles

Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans

Lucas T. van Eijk, Aaron S. E. John, Frank Schwoebel, Luciana Summo, Stéphanie Vauléon, Stefan Zöllner, Coby M. Laarakkers, Matthijs Kox, Johannes G. van der Hoeven, Dorine W. Swinkels, Kai Riecke, Peter Pickkers

Blood (2014) 124 (17): 2643–2646.

https://doi.org/10.1182/blood-2014-03-559484

Published: 2014

Includes: Supplemental data

Journal Articles

Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis

Albertine E. Donker, Reinier A. P. Raymakers, L. Thom Vlasveld, Teus van Barneveld, Rieneke Terink, Natasja Dors, Paul P. T. Brons, Nine V. A. M. Knoers, Dorine W. Swinkels

Blood (2014) 123 (25): 3873–3886.

https://doi.org/10.1182/blood-2014-01-548776

Published: 2014

Includes: Supplemental data

Journal Articles

Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94.

Kai Riecke, MD, Stefan Zöllner, PhD, Malcolm Boyce, MD, Stephanie Vauléon, PhD, Dorine W. Swinkels, MD, PhD, Thomas Dümmler, PhD, Luciana Summo, PharmD PhD, Coby Laarakkers, BSc, Frank Schwoebel, PhD, Frank Fliegert, MD

Blood (2012) 120 (21): 2342.

https://doi.org/10.1182/blood.V120.21.2342.2342

Published: 2012

Journal Articles

Randomized Double Blind Placebo Controlled PK/PD Study On the Effects of a Single Intravenous Dose of the Anti-Hepcidin Spiegelmer Nox-H94 On Serum Iron During Experimental Human Endotoxemia

Lucas van Eijk, MD, Dorine W. Swinkels, MD, PhD, John Aaron, Frank Schwoebel, PhD, Frank Fliegert, MD, Luciana Summo, PharmD PhD, Vauleon Stéphanie, PhD, Coby Laarakkers, BSc, Kai Riecke, MD, Peter Pikkers, MD PhD

Blood (2012) 120 (21): 3452.

https://doi.org/10.1182/blood.V120.21.3452.3452

Published: 2012

Journal Articles

Serum hepcidin: reference ranges and biochemical correlates in the general population

Tessel E. Galesloot, Sita H. Vermeulen, Anneke J. Geurts-Moespot, Siem M. Klaver, Joyce J. Kroot, Dorlene van Tienoven, Jack F. M. Wetzels, Lambertus A. L. M. Kiemeney, Fred C. Sweep, Martin den Heijer, Dorine W. Swinkels

Blood (2011) 117 (25): e218–e225.

https://doi.org/10.1182/blood-2011-02-337907

Published: 2011

Includes: Supplemental data

Journal Articles

Anemia in Hodgkin Lymphoma: The Role of Interleukin-6 and Hepcidin.

Stefan Hohaus, Barbara Vannata, Manuela Giachelia, Maria Ilaria Roselli, Giuseppina Massini, Annarosa Cuccaro, Maria Chiara Tisi, Marianna Criscuolo, Francesco D'Alo, Harold Tjalsma, Dorine W. Swinkels, MD, PhD, Maria Teresa Voso, Giuseppe Leone

Blood (2009) 114 (22): 3656.

https://doi.org/10.1182/blood.V114.22.3656.3656

Published: 2009

Journal Articles

Serum Ferritin Levels Are Associated with Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease.

Luca Valenti, Dorine W. Swinkels, MD, PhD, Larry Burdick, Paola Dongiovanni, Harold Tjalsma, Silvia Fargion, Anna Ludovica Fracanzani

Blood (2009) 114 (22): 5098.

https://doi.org/10.1182/blood.V114.22.5098.5098

Published: 2009

NARROW

Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor Ker-047 for Treatment of Iron Refractory Iron Deficiency Anemia

Iron homeostasis during anemia of inflammation: a prospective study of patients with tuberculosis

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Towards an External Quality Assessment for Next Generation Sequencing in the Diagnosis of Rare Inherited Anaemias

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism

Hepcidin in the diagnosis of iron disorders

Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9

The Donation Interval of 56 Days Requires Extension to 180 Days for Whole Blood Donors to Recover from Disturbances in Iron Homeostasis

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjects a

Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women

International Comparison Study of Toxic Iron Assays in Patients with Iron Overload Disorders

Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans

Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis

Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94.

Randomized Double Blind Placebo Controlled PK/PD Study On the Effects of a Single Intravenous Dose of the Anti-Hepcidin Spiegelmer Nox-H94 On Serum Iron During Experimental Human Endotoxemia

Serum hepcidin: reference ranges and biochemical correlates in the general population

Anemia in Hodgkin Lymphoma: The Role of Interleukin-6 and Hepcidin.

Serum Ferritin Levels Are Associated with Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only